*
homeCompany ProfileMilestone

Milestone

2018Jan
TuNEX(ENIA11) gets approval for the first new biological entity market authorization from TFDA.
2017May
Fill/Finishing line was upgraded, and increased a new container cartridge aseptic line.
Business of CDMO services expands to China market.
2017Mar
Business of CDMO services expands to US market.
2016Nov
Mycenax in-house MBICHO medium has been innovated for improving the competitive capacity of CDMO services.
2016Sep
The third manufacturing line started to construct.
2015Jun
Mycenax signed agreement of contract manufacturing biologics with an Australian biopharma.
Business of CDMO services expands to US market.
2014Dec
Development project of LusiNEX received grants from MEA.
2014Oct
Mycenax signed agreement of contract manufacturing biologics with Japanese biopharma.
CDMO services expands to Japan market.
2014Apr
Completed construction of 2000L bioreactor as the first in Taiwan.
2013Dec
Mycenax began the development project of LusiNEX.
Mycenax Cooperate stock was officially listed on Stock Exchange at Dec. 25 2013.
Mycenax received PIC/S GMP certificate from TFDA.
TuNEX received silver award of Pharmaceutical Technology Research and Development Award from TFDA.
2013Mar
Mycenax signed agreement of contract manufacturing biologics with European biopharma.
CDMO services expanded to EU market.
2012Dec
Mycenax partnered with TSH Biopharm, for TSH to be responsible for phase III clinical trial and NDA submission, and Myce
2011Dec
TFDA approved phase III clinical trial of TuNEX in Taiwan.
2009Oct
TuNEX received approval to enter phase III clinical trial from Korea FDA.
2008Nov
Mycenax received bronze award of Taiwan Biotech industry Awards.
2008Oct
Mycenax was registered as listed company at emerging stock market.
Mycenax was categorized formally as biopharmaceutical company by MEA.
2008Aug
Started to conduct the second tier of MEA Industrial TDP, from Aug. 2008 -
2007Nov
TuNEX was approved to enter phase I/II clinical trial.
2007Apr
The development project of GranNEX started to conduct and was supported by MEA Industrial TDP.
2006Apr
Issued the IPO (4726).
2005Aug
Mycenax conducted Follow-on Biologics project granted by MEA for TuNEX pre-clinical development from Aug. 2005 to Jul. 2
2005Jan
Registered DMF to FDA (DMF no.17981)
2003Oct
Completed construction of biologics plant in Jhunan Science Park.
2002May
Established and installed in Jhunan Science Park.
2001Sep
Myceanx was established in Xindian Dist., New Taipei City.
scroll to Top